INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 201 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2019. The put-call ratio across all filers is 1.09 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $436,000 | -45.1% | 6,930 | +8.1% | 0.00% | -33.3% |
| Q4 2019 | $794,000 | +78.8% | 6,410 | -4.3% | 0.00% | +50.0% |
| Q3 2019 | $444,000 | +69.5% | 6,697 | +103.7% | 0.00% | +100.0% |
| Q2 2019 | $262,000 | -26.2% | 3,287 | +3.5% | 0.00% | -50.0% |
| Q1 2019 | $355,000 | -61.9% | 3,177 | -43.4% | 0.00% | -80.0% |
| Q3 2015 | $931,000 | -30.1% | 5,614 | +1.8% | 0.01% | -23.1% |
| Q2 2015 | $1,332,000 | – | 5,517 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |